What is Orasis Pharmaceuticals?
Orasis Pharmaceuticals is an emerging ophthalmic pharmaceutical enterprise dedicated to addressing significant unmet needs in eye care. The company has garnered industry attention for the development and FDA approval of QLOSI, a prescription eye drop designed to treat presbyopia. By offering a pharmacological alternative to traditional reading glasses, Orasis is effectively disrupting the vision correction market. Their business model centers on leveraging advanced pharmaceutical science to improve patient quality of life, positioning them as a high-growth entity within the life sciences ecosystem. The company's ability to navigate the complex regulatory environment while securing institutional support highlights its operational rigor and scientific credibility.
How much funding has Orasis Pharmaceuticals raised?
Orasis Pharmaceuticals has raised a total of $126M across 4 funding rounds:
Series B
$13M
Series C
$30M
Debt
$15M
Series D
$68M
Series B (2018): $13M with participation from Visionary Ventures
Series C (2020): $30M led by Maverick Ventures, LifeSci Venture Partners, SBI Innovation Fund, Visionary Ventures, Steamboat Ventures, and Bluestem Capital
Series D (2024): $68M supported by Johnson & Johnson Innovation and Arboretum Ventures
Debt (2024): $15M featuring Catalio Capital Management
Key Investors in Orasis Pharmaceuticals
Johnson & Johnson Innovation
A global leader in pharmaceutical manufacturing and healthcare innovation that partners with early-stage businesses to develop transformational medical solutions.
Arboretum Ventures
A Midwest-based healthcare venture capital firm with over two decades of experience focusing on medical devices, life science tools, and tech-enabled care delivery.
Catalio Capital Management
A New York-based investment firm specializing in breakthrough biomedical technology, managing significant assets across private, public, and credit markets.
What's next for Orasis Pharmaceuticals?
With the recent infusion of $68M, Orasis Pharmaceuticals is well-positioned to scale its commercial operations and expand the market penetration of its flagship product. The strategic focus will likely shift toward optimizing supply chain logistics, enhancing physician outreach programs, and potentially exploring pipeline diversification to address other ocular conditions. By maintaining a robust balance sheet, the company is prepared to sustain its competitive advantage against traditional optical solutions. Investors will be closely monitoring the adoption rates of QLOSI as the firm leverages its recent capital injection to solidify its footprint in the global ophthalmology market, ensuring long-term value creation for stakeholders and improved outcomes for patients suffering from age-related vision decline.
See full Orasis Pharmaceuticals company page
